Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosage Form Proportionality of Opicapone in Healthy Subjects
NCT02305329Phase 1Completed
- Sponsor
- BIAL
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of opicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoint: Maximum Observed Plasma Concentration of 9-1067 at 48 hours. Started Feb 2014; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02305329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305329.